Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing
Key Highlights
- ➤Alps Group (ALPS) launches Pharmaco-Interaction unit within MyGenome subsidiary
- ➤CYP450 testing covers seven enzyme isoforms metabolizing approximately 90% of marketed clinical drugs
- ➤PCI makes CYP450 inhibitory IC50 testing commercially available to manufacturers and research institutions
- ➤Alps says PCI converts scientific infrastructure into a revenue-generating capability
- ➤PCI joins Alps’ expanding B2B laboratory services across oncology, genomics, and translational research
Expert Statements
Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc
“Every service we launch is a building block toward becoming Southeast Asia’s integrated life sciences reference platform.”
Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc
“The region has a significant and growing herbal and botanical products industry, yet access to accredited CYP inhibition testing has remained limited. PCI addresses that gap converting our scientific infrastructure into a revenue-generating capability that meets the regulatory standards already demanded by the market.”
Professor Nik Soriani, PCI Scientific Lead at MyGenome
“The assumption that all natural products are inherently safe, especially in consumption with prescription drugs, is one of the most persistent misconceptions in healthcare.”
Professor Nik Soriani, PCI Scientific Lead at MyGenome
“CYP450 inhibition testing is already recommended by the FDA and EMA for clinical and botanical products. PCI intends to make that standard accessible to manufacturers and researchers across Southeast Asia. We are building the reference laboratory Southeast Asia has been missing.”
KUALA LUMPUR, Malaysia, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced the launch of its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing debuting as its first commercial service offering.
The MyGenome laboratory facility in Kuala Lumpur, Malaysia, home to the newly launched Pharmaco-Interaction (PCI) unit.
Get started
Create a free account to read the full story.